Newsfeeds - Spark Newswire

1 minute read

Travere Therapeutics Stock Is Trading Higher On Positive Data From Kidney Disease Candidate

Today, 7:09 PM

Compared to the active control irbesartan, the study met its pre-specified interim primary efficacy endpoint, demonstrating a more than threefold reduction of proteinuria from baseline after 36 weeks of treatment.

TVTX

3 minute read

News

Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

By Benzinga Newsdesk

Today, 7:09 PM

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan, an investigational product candidate for the treatment of IgA

TVTX

1 minute read

Earnings

Travere Therapeutics: Q2 Earnings Insights

By Benzinga Insights

Today, 7:09 PM

Shares of Travere Therapeutics (NASDAQ:TVTX) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 77.27% over the past year to ($0.39), which beat the estimate of ($0.68).

TVTX

22 minute read

Earnings Scheduled For July 29, 2021

By Benzinga Insights

Today, 7:09 PM

Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter.

5 minute read

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More

By Shanthi Rexaline

Today, 7:09 PM

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.

ABBV